SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
... decreased due to lower royalty income.
and development expenses decreased 34%, or ... of our potential products and complete research
and development, including pre-clinical and ... 191,047 146,051 428,739
development 793,503 ...
Novavax Reports Second Quarter 2009 Financial Results
... the completion of two contracts in 2009.
and development costs were $5.3 million for the ... preclinical studies and clinical trials and other research
and development activities; clinical trial ... Operating costs and
and development 5,297 5,380 9,563 ...
EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
... and Pharmacology to Vice-President of Preclinical research
Dr. Fewell possesses more ... He has been instrumental in building EGEN's research
and development team and has helped foster ... Children Hospital. During his active career in research
and development, Dr. Fewell has authored numerous ...
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
... to $386,612 in the same period in 2008.
and development expenses for the second quarter ... of $48,440 and $99,532, respectively. research
and development expenses for the six months ended ... $-
Operating costs and
development 1,376,253 ...
NeurogesX Reports Second Quarter 2009 Results
... to a decline of approximately $1.4 million in research
and development costs. During the second quarter ... ---- ----
development(1) $2,780 ... included in
and development $189 $215 $448 ...
ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA
... from Dr. Hiroyuki Ebinuma of the Tsukuba research
Institute in the journal Clinica Chimica Acta in ... cited in many publications, and is trusted by the research
community worldwide for its consistency and ... to grow. Dr. Kelly Scribner Doering, Market research
Analyst with ALPCO, states, "Adiponectin is ...
GenVec Reports Second Quarter 2009 Financial Results
... program in each period is due mainly to increased research
and process development efforts as compared to ... GenVec received a Small Business Innovation and research
(SBIR) grant from the National Institute of ... $7,576 $7,592
and development 7,096 8,356 14,385 ...
Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services
... Incorporated, a provider of leading discovery research
informatics software tools used for design, ... and global distribution to accelerate discovery research
Early in the drug discovery ... with ChemNavigator's front-end cheminformatics research
tools. These newly combined capabilities will ...
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
... (IPF), which InterMune does not promote.
and development (R&D) expenses in the second ... pre-registration stage. The company also has a research
program focused on an early-stage anti-fibrotic ... and a second-generation HCV protease inhibitor research
program. For additional information about ...
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
... compared to hardware or platform products.
and development expenses were $10.2 million for ... million for the same period in the prior year. research
and development expenses for the second quarter ... Ms. Keller brings more than 25 years of clinical research
experience across a broad range of therapeutic ...
OncoGenex Reports Second Quarter 2009 Financial Results
... to $7.0 million from $5.4 million in 2008.
and development expenses for the second quarter ... in 2008. For the six months ended June 30, 2009 research
and development expenses increased to $5.3 ... in the first six months of 2008 was a Scientific research
and Development (SRED) claim, which offset R D ...
Transposagen Creates a Rat Model of the Human Immune System
... technologies. Knockout rats are pharmaceutical research
models with single gene disruptions that mimic ... research. The production of animal models for research
is a $1.2 billion/year market and the genetically ... care and community engagement. A major national research
center and academic medical center, its faculty ...
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
... items) was $12.6 million.
and development expenses were $6.8 million, and ... related amortization charges, acquired in-process research
and development relating to license agreements ... 25,682 (896) b 24,786
and development 6,833 (739) ...
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
... decrease is mainly a result of a 54% reduction in research
and development expenses for the quarter ended ... related to the closing of CTI's Bresso, Italy research
facility. Net loss attributable to common ... number of shares outstanding and a reduction in research
and development and financing expenses as ...
The Breast Cancer Therapeutics Market in Australia
... explains Carole Gaffud, Frost & Sullivan research
Analyst. "There are several new targeted ... care.
Frost & Sullivan's latest research
service on The Breast Cancer Therapeutics Market ... CEO and the CEO's Growth Team with disciplined research
and best practice models to drive the generation, ...
UCLA welcomes startup to new incubator space at California NanoSystems Institute
... was established in March to nurture early-stage research
and accelerate the commercial translation of ... with access to CNSI core lab facilities for research
"We consider ourselves very ... startup companies and early-stage technology research
projects that originate at UCLA. The incubator ...
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
... original agreement, a $1.8 million decrease in research
and development expenses related to KRX-0401, and a $1.0 million decrease in research
and development expenses related to the cessation ... attributable to a $26.9 million decrease in research
and development expenses related to the cessation ...
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Amicus continues to invest in research
to assess the potential for applying its ... in Parkinson's disease and is investing in new research
aimed at evaluating disease targets for other ... (1985 - 1987), and President and CEO of Bethesda research
Labs (1982 - 1983). He currently serves on the ...
GeoVax Labs, Inc. Provides Clinical Studies Update
... University of Rochester; Fred Hutchinson Cancer research
Center, Seattle; the San Francisco Department of ... developer of the vaccine and Senior V.P. of research
and Development. "The therapeutic trials should ... developed by Dr. Harriet Robinson, Senior V.P. of research
and Development, through a collaboration of ...
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... depressed gross
margin for that product.
and development ("R&D")
... 96.4 142.9 180.0 233.2
and development(2) 158.7 136.4 ... and $19.1 million have been
reclassified from research
and development to Selling, general ...
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
... increase in net loss was primarily due to higher research
and development expenses. research
and development expenses in the second quarter of ... progress and likelihood of success of its product research
and development programs, the timing and status ...
The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
... Center's resources to continue its groundbreaking research
in many promising areas such as cell processing, ... for advancing NIH-sponsored clinical research
with this generous donation and hope that other ... ability of the NIH to pursue new and cutting-edge research
by freeing up much needed resources," said Marc ...
SK Life Sciences has Licensed Pristima
... Inc. (SKLSI), has licensed Pristima for its research
and Development facility in Fair Lawn, New ... Inc. (SKLSI), has licensed Pristima for its research
and Development facility in Fair Lawn, New Jersey.
After extensive research
and evaluation of the products on the market, ...
New angle on gecko research
This latest development in gecko adhesive research
will be published Wed., Aug. 5, at 00:001 BST, by ... well as in the lab. Insights gained through basic research
assist them in designing experiments through an ... to complex problems.
The goal of Russell's research
is to try to understand this complex traction ...
Plastics that convert light to electricity could have a big impact
... electricity and can be easily manufactured.
team headed by David Ginger, a University of ... materials considered basic to organic solar cell research
because their response to forces such as heating ... are Liam Pingree and Obadiah Reid of the UW. The research
was funded by the National Science Foundation and ...
Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
... plan to discontinue its in-house preclinical research
operations and reduce its workforce by approximately 12 percent effective March 31, 2009.
and development (R&D) expenses were $5.7 ... and uncertainties associated with the Company's research
and development activities; the results of ...
Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
... was awarded as government participation in research
expenses for the period of ... Oramed's technology is based on
over 25 years of research
by top research
scientists at Jerusalem's Hadassah
SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS
... specified conditions. Senomyx will also receive research
fees, payments upon the achievement of specified ... revenue in 2009 compared to 2008.
and development expenses, including non-cash ... the second quarter of 2008, a decrease of 3%. research
and development expenses, including non-cash ...
Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2009
... ======== ========
and development expenses increased $187,000 ... products, the levels and particular directions of research
by the Company's customers, the impact of the growing number of producers of biotechnology research
products and related price competition, general ...
OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd.
... 10 Pharmaceutical, leading Academic and Clinical research
Organizations, will also benefit from working ... the fastest growing segments of the clinical research
industry, according to market research
firm, Health Industry Insights. This growth ...
W.M. Keck Foundation Awards $1 Million to Hutchinson Center Scholar to Study How Cells Go Awry
... how cancer cells cheat - Fred Hutchinson Cancer research
Center basic scientist Wenying Shou, Ph.D., has ... and Bruce Clurman, M.D., Ph.D., of the Clinical research
and Human Biology divisions (1999).
The ... the Keck Distinguished Young Scholars in Medical research
program was designed to support ...
National Institutes of Health Chooses Web of Science(R) to Power electronic Scientific Portfolio Assistant (eSPA)
... in creating grant portfolios and tracking research
outputs and outcomes, including publications and ... Vice President, Scientific & Scholarly research
at Thomson Reuters. "We are proud that Web of ... continues to be chosen by NIH and other leading research
As the prime contractor on ...
International Milk Genomics & Human Health Symposium Speaker Program Announced
... under the organization of the California Dairy research
Foundation (CDRF), the symposium will gather ... milk and Michael Affolter of the Nestlé research
Center addressing qualitative and quantitative ... data exchange, coordination of pre-competitive research
to develop baseline data, and providing a ...
NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
... Wu completed numerous licensing agreements and research
collaborations with companies including Novartis, ... development for Quintiles-BRI, a clinical research
organization, after working for 16 years at ... beginning as a chemist at the Syntex research
Institute of Pharmaceutical Sciences and ...
Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software
... (CTMS) tool for the pharmaceutical clinical research
community to reduce both costs and effort in ... (CTMS) tool for the pharmaceutical clinical research
community to reduce both costs and effort in ... software platform will benefit the clinical research
community by taking much of the manual work out ...
Model predicts evolution of Mediterranean landscape following fires
... An international research
team has developed a mathematical and ... of forest fires. In order to carry out this research
study, published recently in the journal ... affecting Mediterranean areas. In fact, this research
study is part of a broader study into changes in ...
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
... by the year-to-date cash utilization.
and development expenses were $4.6 million for ... ---- ----
and development $4,648 $5,501 ... ended June 30, 2009 and 2008, respectively. research
expense and general and ...
Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
... which is the venture capital affiliate of Cato research
Ltd., a global contract research
and development organization currently assisting ... to further advance its multiple myeloma research
and development program with the goal of ...
Growing Midwestern Clinical Research Organization Selects OmniComm Systems to Provide eClinical Solutions for Phase IV Studies
... trials announced today that a growing US Clinical research
Organization (CRO) has selected OmniComm to ... solutions to pharmaceutical, biotechnology, research
and medical device organizations that conduct ... and efficiently capitalize on their clinical research
investments. OmniComm Systems, Inc. has corporate ...
Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
... orthobiologics product portfolio based on research
and development by Cardium's Tissue Repair ... and (3) a substantial body of pre-clinical research
and development supporting the use of GAM to ... enhance spinal fusions. A pre-clinical research
study, conducted by Cardium's Tissue Repair ...